Genome-wide association study of aromatase inhibitor discontinuation due to musculoskeletal symptoms
暂无分享,去创建一个
J. Douglas | D. Hayes | T. Skaar | V. Stearns | J. Rae | A. Storniolo | Z. Desta | K. Kidwell | N. Henry | D. Hertz | C. Gersch | Robert M. Miller | N. L. Henry
[1] A. Blackford,et al. Further Evidence That OPG rs2073618 Is Associated With Increased Risk of Musculoskeletal Symptoms in Patients Receiving Aromatase Inhibitors for Early Breast Cancer , 2021, Frontiers in Genetics.
[2] A. Benson,et al. Prospective validation of genetic predictors of aromatase inhibitor-associated musculoskeletal symptoms (AIMSS) in a racially diverse cohort: Results from ECOG-ACRIN E1Z11. , 2021 .
[3] C. Adithan,et al. Polymorphisms of T- cell leukemia 1A gene loci are not related to the development of adjuvant letrozole-induced adverse events in breast cancer , 2021, PloS one.
[4] C. Loprinzi,et al. Management of Aromatase Inhibitor-Induced Musculoskeletal Symptoms. , 2020, JCO oncology practice.
[5] Jason C. Young,et al. The Evolution of Duplicated Genes of the Cpi-17/Phi-1 (ppp1r14) Family of Protein Phosphatase 1 Inhibitors in Teleosts , 2020, International journal of molecular sciences.
[6] B. Yaremko,et al. Genetic and clinical predictors of arthralgia during letrozole or anastrozole therapy in breast cancer patients , 2020, Breast Cancer Research and Treatment.
[7] A. Leroux,et al. Identification of Specific Tumor Markers in Vulvar Carcinoma Through Extensive Human Papillomavirus DNA Characterization Using Next Generation Sequencing Method. , 2020, Journal of lower genital tract disease.
[8] A. Boyle,et al. Predicting functional variants in enhancer and promoter elements using RegulomeDB , 2019, Human mutation.
[9] Arthur S Slutsky,et al. The plasma peptides of ovarian cancer , 2018, Clinical Proteomics.
[10] J. Perea,et al. A novel nonsense variant in SUPT20H gene associated with Rheumatoid Arthritis identified by Whole Exome Sequencing of multiplex families , 2018, bioRxiv.
[11] G. Rosner,et al. A phase II study evaluating the efficacy of zoledronic acid in prevention of aromatase inhibitor-associated musculoskeletal symptoms: the ZAP trial , 2018, Breast Cancer Research and Treatment.
[12] J. Rae,et al. Attempted replication of SNPs in RANKL and OPG with musculoskeletal adverse events during aromatase inhibitor treatment for breast cancer , 2017, Physiological genomics.
[13] Ana Cernea,et al. Genomic risk prediction of aromatase inhibitor‐related arthralgia in patients with breast cancer using a novel machine‐learning algorithm , 2017, Cancer medicine.
[14] C. Moinpour,et al. Randomized, Multicenter, Placebo-Controlled Clinical Trial of Duloxetine Versus Placebo for Aromatase Inhibitor-Associated Arthralgias in Early-Stage Breast Cancer: SWOG S1202. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] Gary D Bader,et al. Association analysis identifies 65 new breast cancer risk loci , 2017, Nature.
[16] P. Neven,et al. Associations Between Patient and Anthropometric Characteristics and Aromatase Inhibitor Discontinuation , 2017, Clinical breast cancer.
[17] M. Kris,et al. Overall Survival Results of a Trial Assessing Patient-Reported Outcomes for Symptom Monitoring During Routine Cancer Treatment , 2017, JAMA.
[18] D. Kroetz,et al. Genetic advances uncover mechanisms of chemotherapy‐induced peripheral neuropathy , 2017, Clinical pharmacology and therapeutics.
[19] J. Rae,et al. Germline genetic predictors of aromatase inhibitor concentrations, estrogen suppression and drug efficacy and toxicity in breast cancer patients. , 2017, Pharmacogenomics.
[20] G. Gervasini,et al. Polymorphisms in ABCB1 and CYP19A1 genes affect anastrozole plasma concentrations and clinical outcomes in postmenopausal breast cancer patients , 2017, British journal of clinical pharmacology.
[21] D. Beckwée,et al. Prevalence of aromatase inhibitor-induced arthralgia in breast cancer: a systematic review and meta-analysis , 2017, Supportive Care in Cancer.
[22] Matthias W. Beckmann,et al. Evidence that the 5p12 Variant rs10941679 Confers Susceptibility to Estrogen-Receptor-Positive Breast Cancer through FGF10 and MRPS30 Regulation , 2016, American journal of human genetics.
[23] Alan M. Kwong,et al. Next-generation genotype imputation service and methods , 2016, Nature Genetics.
[24] Tom R. Gaunt,et al. Systematic identification of genetic influences on methylation across the human life course , 2016, Genome Biology.
[25] Todd C. Skaar,et al. Patient-Reported Outcomes and Early Discontinuation in Aromatase Inhibitor-Treated Postmenopausal Women With Early Stage Breast Cancer , 2016, The oncologist.
[26] J. Forbes,et al. Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials , 2015, The Lancet.
[27] Lei Liu,et al. RANKL and OPG Polymorphisms Are Associated with Aromatase Inhibitor-Related Musculoskeletal Adverse Events in Chinese Han Breast Cancer Patients , 2015, PloS one.
[28] L. Moscetti,et al. Adjuvant Aromatase Inhibitor Therapy in Early Breast Cancer: What Factors Lead Patients to Discontinue Treatment? , 2015, Tumori.
[29] P. Neven,et al. CYP19A1 polymorphisms and clinical outcomes in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1–98 trial , 2015, Breast Cancer Research and Treatment.
[30] Joris M. Mooij,et al. MAGMA: Generalized Gene-Set Analysis of GWAS Data , 2015, PLoS Comput. Biol..
[31] H. Putter,et al. Germline variants in the CYP19A1 gene are related to specific adverse events in aromatase inhibitor users: a substudy of Dutch patients in the TEAM trial , 2014, Breast Cancer Research and Treatment.
[32] D. Wallwiener,et al. COMPliance and Arthralgia in Clinical Therapy: the COMPACT trial, assessing the incidence of arthralgia, and compliance within the first year of adjuvant anastrozole therapy. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.
[33] Wei Xiao,et al. The p38-interacting Protein (p38IP) Regulates G2/M Progression by Promoting α-Tubulin Acetylation via Inhibiting Ubiquitination-induced Degradation of the Acetyltransferase GCN5* , 2013, The Journal of Biological Chemistry.
[34] J. Farrar,et al. Joint pain severity predicts premature discontinuation of aromatase inhibitors in breast cancer survivors , 2013, BMC Cancer.
[35] Qingyuan Zhang,et al. Indications of Clinical and Genetic Predictors for Aromatase Inhibitors Related Musculoskeletal Adverse Events in Chinese Han Women with Breast Cancer , 2013, PloS one.
[36] A. Díez-Pérez,et al. Genetic determinants of aromatase inhibitor-related arthralgia: the B-ABLE cohort study , 2013, Breast Cancer Research and Treatment.
[37] Ellen T. Gelfand,et al. The Genotype-Tissue Expression (GTEx) project , 2013, Nature Genetics.
[38] Steffi Oesterreich,et al. Genetic associations with toxicity-related discontinuation of aromatase inhibitor therapy for breast cancer , 2013, Breast Cancer Research and Treatment.
[39] Jane E. Carpenter,et al. A meta-analysis of genome-wide association studies of breast cancer identifies two novel susceptibility loci at 6q14 and 20q11. , 2012, Human molecular genetics.
[40] Eurie L. Hong,et al. Annotation of functional variation in personal genomes using RegulomeDB , 2012, Genome research.
[41] Lang Li,et al. Predictors of aromatase inhibitor discontinuation as a result of treatment-emergent symptoms in early-stage breast cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[42] Lang Li,et al. Plasma Letrozole Concentrations in Postmenopausal Women With Breast Cancer Are Associated With CYP2A6 Genetic Variants, Body Mass Index, and Age , 2011, Clinical pharmacology and therapeutics.
[43] Dawn L. Hershman,et al. Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer , 2011, Breast Cancer Research and Treatment.
[44] Yusuke Nakamura,et al. Genome-wide associations and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitors. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[45] M. Banerjee,et al. A prospective study of aromatase inhibitor‐associated musculoskeletal symptoms and abnormalities on serial high‐resolution wrist ultrasonography , 2010, Cancer.
[46] G. Uhl,et al. Effect of KEPI (Ppp1r14c) deletion on morphine analgesia and tolerance in mice of different genetic backgrounds: when a knockout is near a relevant quantitative trait locus , 2010, Neuroscience.
[47] Jemma L. Webber,et al. Coordinated regulation of autophagy by p38α MAPK through mAtg9 and p38IP , 2010, The EMBO journal.
[48] J. Farrar,et al. Patterns and risk factors associated with aromatase inhibitor‐related arthralgia among breast cancer survivors , 2009, Cancer.
[49] J. Cuzick,et al. Risk factors for joint symptoms in patients enrolled in the ATAC trial: a retrospective, exploratory analysis. , 2008, The Lancet. Oncology.
[50] H. Greenlee,et al. Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[51] S. Cummings,et al. Aromatase inhibitors and the syndrome of arthralgias with estrogen deprivation. , 2005, Arthritis and rheumatism.
[52] E. Perez,et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. , 2004, The New England journal of medicine.
[53] P. Schultz,et al. Cancer Survivors , 2002, AAOHN journal : official journal of the American Association of Occupational Health Nurses.
[54] G. Uhl,et al. KEPI, a PKC-dependent Protein Phosphatase 1 Inhibitor Regulated by Morphine* , 2002, The Journal of Biological Chemistry.
[55] Krishna R. Kalari,et al. Vitamin D Levels, Vitamin D Receptor Polymorphisms, and Inflammatory Cytokines in Aromatase Inhibitor‐Induced Arthralgias: An Analysis of CCTG MA.27 , 2018, Clinical breast cancer.